The Netherlands Authority for Consumers and Markets (ACM) has launched a market investigation into the pricing of food products within Dutch supermarkets. This inquiry aims to scrutinise the price structures and formations associated with the typical grocery basket purchased by consumers, the regulator said in an official statement. The investigation was instigated following concerns that the prices of certain food items in the Netherlands are significantly higher than those in neighbouring countries. ...

Global X Hydrogen ETF (HYDR) has been hovering around a 52-week high lately. The ETF has gained 16.7% over the past week and has advanced 25.8% over the past month (as of Sept. 17, 2025).The ETF’s second holding, Plug Power (PLUG) stock — which takes about 18% of the fund’s weight — surged 19.1% on Sept. 17, 2025, and skyrocketed 40.6% over the past week (as of Sept. 17, 2025). The ETF’s top holding — Bloom Energy (BE) stock — gained 8.7% on Sept. 17, 2025. The BE stock advanced 24.6% over the past week.Not ...

Group 1 - The article does not provide any specific content related to a company or industry, as it only contains a prompt to sign in to access a portfolio [1]

Core Viewpoint - Artificial intelligence (AI) is a leading investment theme, with Palantir (PLTR) emerging as a significant beneficiary, particularly with a potential $1 billion contract with the U.K. Ministry of Defence [1][2]. Group 1: Contract Details - The U.K. Ministry of Defence is preparing to sign a deal worth approximately $1 billion (£750 million) with Palantir during President Donald Trump's visit [1]. - The agreement will involve the Royal Navy and will enable Palantir to deploy its AI systems for data analysis across the U.K. military, focusing on recruitment gaps, deployment suitability, and maintenance schedules [2]. Group 2: Investment Commitment - Palantir has committed to investing up to $2 billion in the U.K. over the next five years, reinforcing its position in the AI and defense sectors [3]. Group 3: Company Overview - Founded in 2003, Palantir has become a global technology leader, providing advanced intelligence and operational planning tools to governments and enterprises [4]. - The company's success is driven by its Artificial Intelligence Platform (AIP), which integrates generative AI into business workflows to enhance decision-making and efficiency [4]. Group 4: Stock Performance - Palantir's market capitalization is approximately $399.3 billion, with its stock price increasing by 388.4% over the past year, significantly outperforming the S&P 500 Index's 18.2% gain [5]. - Year-to-date, Palantir shares have risen by 122.6%, again surpassing the broader market's 12.2% return, although the stock is currently trading about 11.4% below its recent peak of $190 [6].

VANCOUVER, British Columbia, September 19, 2025 – TheNewswire - Gamma Resources Ltd. (TSX-V: GAMA; OTCPK: MLLOF; Frankfurt: MRDN) (“Gamma” or the “Company”) is pleased to announce that it has successfully renegotiated the terms of its existing promissory note (the “Note”) with two US investors (the “Lenders”), providing the Company with enhanced flexibility and reinforcing the strong, cooperative relationship between the parties.Under the revised terms, Gamma has agreed to a modified repayment schedule desi ...

Core Points - M/I Homes, Inc. has amended its credit agreement, increasing borrowing availability from $650 million to $900 million and extending the maturity to September 2030 [1][2] - The company reported zero borrowings under its existing credit facility and a cash position of $800 million as of June 30, 2025 [2] - Homebuilding debt-to-capital ratio stands at 18%, while the net debt-to-capital ratio is negative 3% [2] Company Overview - M/I Homes, Inc. is a leading homebuilder in the United States, with operations in multiple states including Ohio, Indiana, Illinois, Minnesota, Michigan, Florida, Texas, North Carolina, and Tennessee [2]

Outliving your money is the biggest nightmare for most retirees. In fact, 64% of U.S. adults surveyed by Allianz Life said they were more afraid of running out of money in retirement than dying [1]. Must Read But for some retirees, this fear is so crippling that it compels them to chronically underspend and end up with more money than they started with. In fact, an ultra-frugal retiree with $1 million can actually end up with $2 million or more by the end of their life. Underspending As a general rul ...

Apple's iPhone 17 going on sale today. Fans lining up from Beijing to London to get their hands on the latest piece of hardware where in early a signal shows strong demand for the iPhone 17 lineup. But Apple's still grappling uh with AI issues, increasing competition, and we're going to take you live to Apple's flagship store uh here in New York City for that opening uh at 8:00 a.m. Eastern time. Ahead on Squawkbox, is it safe for investors to get behind Intel.The stocks had a rough run. We're going to talk ...

NORTH YORK, ON / ACCESS Newswire / September 19, 2025 / ZTEST Electronics Inc. ("ZTEST" or the "Company") (CSE:ZTE)(OTCID:ZTSTF) is pleased to announce that it will participate in the upcoming Annual Smallcap Discoveries Conference in Vancouver, BC. CEO Steve Smith will be presenting on September 30, 2025, and will speak about the Company's recent results, longer-term strategies and will be answering questions at the conclusion of the presentation. ...

Core Viewpoint - Nuvation Bio Inc. has received approval from Japan's Ministry of Health, Labour and Welfare for its drug IBTROZITM (taletrectinib) to treat adult patients with ROS1-positive unresectable, advanced, and/or recurrent non-small cell lung cancer [1] Company Summary - Nuvation Bio Inc. is a global oncology company focused on addressing significant challenges in cancer treatment [1] - The approval of IBTROZITM marks a significant milestone for the company in expanding its product offerings in the oncology market [1] Industry Summary - The approval of IBTROZITM highlights the growing importance of targeted therapies in the treatment of non-small cell lung cancer, particularly for specific genetic mutations like ROS1 [1] - The collaboration with Nippon Kayaku under an exclusive license agreement indicates a strategic partnership aimed at enhancing the commercialization of innovative cancer treatments in Japan [1]